Vanguard Group
TWST icon

Vanguard Group’s Twist Bioscience TWST Stock Holding History

Vanguard Group’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$183M Buy
5,776,198
+8,049
+0.1% +$251K ﹤0.01% 1587
2025
Q3 		$162M Sell
5,768,149
-63,162
-1% -$1.91M ﹤0.01% 1654
2025
Q2 		$215M Sell
5,831,311
-36,148
-0.6% -$1.25M ﹤0.01% 1473
2025
Q1 		$230M Buy
5,867,459
+60,276
+1% +$2.71M ﹤0.01% 1418
2024
Q4 		$270M Buy
5,807,183
+189,791
+3% +$8.58M ﹤0.01% 1393
2024
Q3 		$254M Buy
5,617,392
+25,101
+0.4% +$1.19M ﹤0.01% 1419
2024
Q2 		$276M Buy
5,592,291
+130,059
+2% +$5.3M 0.01% 1315
2024
Q1 		$187M Sell
5,462,232
-13,090
-0.2% -$472K ﹤0.01% 1563
2023
Q4 		$202M Sell
5,475,322
-115,652
-2% -$2.67M ﹤0.01% 1500
2023
Q3 		$113M Sell
5,590,974
-292,411
-5% -$6.43M ﹤0.01% 1737
2023
Q2 		$120M Buy
5,883,385
+185,038
+3% +$2.77M ﹤0.01% 1748
2023
Q1 		$85.9M Buy
5,698,347
+469,002
+9% +$10.4M ﹤0.01% 1896
2022
Q4 		$125M Buy
5,229,345
+310,380
+6% +$9M ﹤0.01% 1687
2022
Q3 		$173M Sell
4,918,965
-13,562
-0.3% -$576K 0.01% 1468
2022
Q2 		$172M Buy
4,932,527
+141,453
+3% +$5.01M ﹤0.01% 1521
2022
Q1 		$237M Buy
4,791,074
+467,466
+11% +$25.9M 0.01% 1444
2021
Q4 		$335M Buy
4,323,608
+35,010
+0.8% +$3.59M 0.01% 1261
2021
Q3 		$459M Buy
4,288,598
+108,938
+3% +$12.5M 0.01% 1026
2021
Q2 		$557M Buy
4,179,660
+220,331
+6% +$25.6M 0.01% 927
2021
Q1 		$490M Buy
3,959,329
+435,943
+12% +$66.2M 0.01% 962
2020
Q4 		$498M Buy
3,523,386
+1,140,123
+48% +$126M 0.01% 880
2020
Q3 		$181M Buy
2,383,263
+724,962
+44% +$45.1M 0.01% 1342
2020
Q2 		$75.1M Buy
1,658,301
+155,845
+10% +$5.59M ﹤0.01% 1804
2020
Q1 		$45.9M Buy
1,502,456
+400,529
+36% +$10.8M ﹤0.01% 1904
2019
Q4 		$23.1M Buy
1,101,927
+8,245
+0.8% +$193K ﹤0.01% 2460
2019
Q3 		$26.1M Buy
1,093,682
+38,208
+4% +$1.11M ﹤0.01% 2351
2019
Q2 		$30.6M Buy
1,055,474
+805,251
+322% +$21.3M ﹤0.01% 2332
2019
Q1 		$5.8M Buy
250,223
+41,766
+20% +$944K ﹤0.01% 3086
2018
Q4 		$4.81M Buy
+208,457
New +$4.62M ﹤0.01% 3105

Other funds holding TWST

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group's TWST Position: Q4 2025 in Review

Vanguard Group increased its Twist Bioscience (TWST) stake by 0.14% in Q4 2025, buying an estimated $251K and bringing the position to 5,776,198 shares worth $183M. The position accounts for ﹤0.01% of the portfolio, ranked #1587.

Vanguard Group first reported a position in TWST in Q4 2018 and has held it in 29 quarters since. The position peaked at $557M in Q2 2021. 244 funds tracked by Wall St. Rank hold TWST as of Q4 2025.

  • Vanguard Group held 5,776,198 shares of Twist Bioscience worth $183M as of Q4 2025.
  • Vanguard Group bought 8,049 Twist Bioscience shares in Q4 2025, an estimated $251K.
  • Twist Bioscience made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1587 holding.
  • Vanguard Group first reported a position in Twist Bioscience in Q4 2018 and has held it in 29 quarters since.
  • Vanguard Group's Twist Bioscience position peaked at $557M in Q2 2021.
  • 244 funds tracked by Wall St. Rank held Twist Bioscience as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.